Immune globulin-ifas (Intravenous)
Medically reviewed by Drugs.com. Last updated on Apr 30, 2022.
Warning: Thrombosis, Renal Dysfunction, and Acute Renal FailureThrombosis may occur with immune globulin intravenous (IGIV) products, including immune globulin-ifas. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Immune globulin-ifas does not contain sucrose.For patients at risk of thrombosis, renal dysfunction, or renal failure, administer immune globulin-ifas at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity .
Commonly used brand name(s)
In the U.S.
- Panzyga
Available Dosage Forms:
- Solution
Therapeutic Class: Immune Serum
Uses for immune globulin-ifas
Immune globulin-ifas injection contains antibodies that make your immune system stronger. It is used for patients who have primary humoral immunodeficiency (PI), including congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and other severe combined immune system problems. It is also used to raise your platelet counts to control or prevent bleeding in patients with chronic immune thrombocytopenia (ITP). Immune globulin-ifas is also used to improve nerve and muscle problems in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Immune globulin-ifas is to be given only by or under the supervision of your doctor.
Before using immune globulin-ifas
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For immune globulin-ifas, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to immune globulin-ifas or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of immune globulin-ifas injection in children 2 years of age and older. Safety and efficacy have not been established in children with ITP or CIDP or in children younger than 2 years of age to treat primary humoral immunodeficiency, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, or Wiskott-Aldrich syndrome.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of immune globulin-ifas injection in the elderly. However, elderly patients are more likely ..
